Increased microRNA-34c abundance in Alzheimer’s disease circulating blood plasma

• Main Authors: Shephali eBhatnagar, Howard eChertkow, Hyman M Schipper, Vikranth eShetty, Zongfei eYuan, Timothy eJones, Samantha eJenkins, Eugenia eWang
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2014-02-01
• Series: Frontiers in Molecular Neuroscience
• Subjects: Alzheimer's disease; miR-34a; synaptic dysfunction; peripheral blood mononuclear cells; neuronal survival; plasma microRNA
• Online Access: http://journal.frontiersin.org/Journal/10.3389/fnmol.2014.00002/full

Circulating microRNAs, present either in the cellular component, peripheral blood mononuclear cells (PBMC), or in cell-free plasma, have emerged as biomarkers for age-dependent systemic, disease-associated changes in many organs. Previously, we have shown that microRNA (miR)-34a is increased in circulating PBMC of Alzheimer’s disease (AD) patients. In the present study, we show that this microRNA’s sister, miR-34c, exhibits even greater increase in both cellular and plasma components of AD circulating blood samples, compared to normal age-matched controls. Statistical analysis shows the accuracy of levels of miR-34c assayed by receiver operating characteristic (ROC) analysis: the area under the curve is 0.99 (p < 0.0001) and the 95% confidence level extends from 0.97 to 1. Pearson correlation between miR-34c levels and mild and moderate AD, as defined by the mini-mental state examination (MMSE), shows an r-value of -0.7, suggesting a relatively strong inverse relationship between the two parameters. These data show that plasma levels of microRNA 34c are much more prominent in AD than those of its sister, miR-34a, or than its own level in PBMC. Transfection studies show that miR-34c, as does its sister miR-34a, represses the expression of several selected genes involved in cell survival and oxidative defense pathways, such as Bcl2, SIRT1 and others, in cultured cells. Taken together, our results indicate that increased levels of miR-34c in both PBMC and plasma may reflect changes in circulating blood samples in AD patients, compared to age-matched normal controls.